서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 8 of 8

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2011-06	The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 Van Cutsem, E.; Dicato, M.; Geva, R.; Arber, N.; Bang, Y.; Benson, A.; Cervantes, A.; Diaz-Rubio, E.; Ducreux, M.; Glynne-Jones, R.; Grothey, A.; Haller, D.; Haustermans, K.; Kerr, D.; Nordlinger, B.; Marshall, J.; Minsky, B. D.; Kang, Y. K.; Labianca, R.; Lordick, F.; Ohtsu, A.; Pavlidis, N.; Roth, A.; Rougier, P.; Schmoll, H. J.; Sobrero, A.; Tabernero, J.; Van de Velde, C.; Zalcberg, J. Annals of Oncology, Vol.22, pp.v1-v9	DOI
2017-02	Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study Faivre, S.; Niccoli, P.; Castellano, D.; Valle, J. W.; Hammel, P.; Raoul, J. -L.; Vinik, A.; Van Cutsem, E.; Bang, Y. -J.; Lee, S. -H.; Borbath, I.; Lombard-Bohas, C.; Metrakos, P.; Smith, D.; Chen, J. -S.; Ruszniewski, P.; Seitz, J. -F.; Patyna, S.; Lu, D. R.; Ishak, K. J.; Raymond, E. Annals of Oncology, Vol.28 No.2, pp.339-343	DOI
2017-06	A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification Van Cutsem, E.; Bang, Y. -J.; Mansoor, W.; Petty, R. D.; Chao, Y.; Cunningham, D.; Ferry, D. R.; Smith, N. R.; Frewer, P.; Ratnayake, J.; Stockman, P. K.; Kilgour, E.; Landers, D. Annals of Oncology, Vol.28 No.6, pp.1316-1324	DOI
2018-10	Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300 Bang, Y. -J.; Ruiz, E. Yanez; Van Cutsem, E.; Lee, K. -W.; Wyrwicz, L.; Schenker, M.; Alsina, M.; Ryu, M. -H.; Chung, H. -C.; Evesque, L.; Al-Batran, S. -E.; Park, S. H.; Lichinitser, M.; Boku, N.; Moehler, M. H.; Hong, J.; Xiong, H.; Hallwachs, R.; Conti, I.; Taieb, J. Annals of Oncology, Vol.29 No.10, pp.2052-2060	DOI
2020-02	Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group Andre, T.; Vernerey, D.; Im, S. A.; Bodoky, G.; Buzzoni, R.; Reingold, S.; Rivera, F.; McKendrick, J.; Scheithauer, W.; Ravit, G.; Fountzilas, G.; Yong, W. P.; Isaacs, R.; Osterlund, P.; Liang, J. T.; Creemers, G. J.; Rakez, M.; Van Cutsem, E.; Cunningham, D.; Tabernero, J.; de Gramont, A. Annals of Oncology, Vol.31 No.2, pp.246-256	DOI
2021-08	Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study Van Cutsem, E.; Valderrama, A.; Bang, Y. -J.; Fuchs, C. S.; Shitara, K.; Janjigian, Y. Y.; Qin, S.; Larson, T. G.; Shankaran, V.; Stein, S.; Norquist, J. M.; Kher, U.; Shah, S.; Alsina, M. Esmo Open, Vol.6 No.4, p. 100189	DOI
2021-09	SPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) Lordick, F.; Shitara, K.; Al-Batran, S. -E; Bang, Y. -J; Catenacci, D.; Enzinger, P.; Ilson, D.; Kim, S.; Shah, M. A.; Van Cutsem, E.; Xu, R. -H; Arozullah, A.; Park, J. W.; Ajani, J. Oncology Research and Treatment, Vol.44, pp.218-218
2021-09	Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma Shitara, K.; Ozguroglu, M.; Bang, Y-J; Di Bartolomeo, M.; Mandala, M.; Ryu, M-H; Caglevic, C.; Chung, H. C.; Muro, K.; Van Cutsem, E.; Kobie, J.; Cristescu, R.; Aurora-Garg, D.; Lu, J.; Shih, C-S; Adelberg, D.; Cao, Z. A.; Fuchs, C. S. Annals of Oncology, Vol.32 No.9, pp.1127-1136	DOI

1